Drugs / MP0250
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03418532 | Mar 2018 → Aug 2019 | non-small cell lung carcinoma | Molecular Partners AG | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03136653 | May 2017 → Oct 2020 | plasma cell myeloma | Molecular Partners AG | Completed | No outcome recorded |
| Phase 1/2 | NCT02194426 | Jul 2014 → Feb 2018 | neoplasm | Molecular Partners AG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MP0250 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02194426 ↗ |
| Action | Inhibit | “MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with the aim of disrupting the tumor microenvironment.” PMID 33301375 ↗ Dec 2020 |
| Modality | Protein / enzyme biologic | “A first-in-human study was performed with MP0250, a DARPin drug candidate.” PMID 33301375 ↗ Dec 2020 |
| Route | Intravenous | “Intravenous application by infusion of MP0250” NCT02194426 ↗ |